Full-Time

Associate Director

Statistical Programming

Posted on 11/21/2024

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using synthetic lethality

Biotechnology
Healthcare

Senior

Boston, MA, USA

Hybrid position requiring in-office presence.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Python
R
Data Analysis
Requirements
  • Bachelor’s or Master’s degree in statistics, life sciences, computer science, or related field with at least 8 years’ statistical programming experience
  • Solid understanding of industry standards applicable to clinical study data and regulatory reporting requirements including eCTD and CDISC implementation
  • Expert level in SAS programming (Base, Macro, STAT, GRAPH, SQL) is essential; with experience delivering complex programming assignments, macros, and analyses
  • Experience with R and Python is desirable
  • Experience in oncology preferred
  • Extensive experience in early-phase clinical studies including programming and validation of SDTM and ADaM data sets, tables, listings and figures
  • Experience managing CROs for outsourced statistical programming activities
  • Expertise in the requirements and technology to support electronic submissions
  • Experience with BLA, NDA/sNDA submissions to FDA/EMA preferred
  • Strong analytical and communication skills
Responsibilities
  • Lead and manage the statistical programming activities for clinical trials and studies, ensuring high-quality and timely deliverables for CSR, publications, presentations, various reports for health authority submissions, clinical data review, and ad hoc analysis either internally or through CRO partners
  • Develop, validate, and maintain analysis datasets (SDTM, ADaM), tables, listings, and figures, TLFs) in accordance with regulatory guidelines and internal standards
  • Review key clinical study or program documents
  • Perform complex statistical analyses and simulations using SAS to support clinical trial design and data interpretation; manage macro library and templates for efficiently preparing, processing, analyzing clinical data and validating analysis results
  • Provide expertise in statistical programming for regulatory submissions (e.g., FDA, EMA), including electronic submission standards (eCTD)
  • Participate in Tango’s Data Governance Team to build and maintain secure statistical computing and programming infrastructure
  • Collaborate with biostatisticians, data managers, and cross-functional team members to define programming strategies and requirements, establish project timelines, and perform statistical analyses
  • Manage and provide oversight of CROs to ensure high-quality statistical analysis deliverables (datasets, TLFs, etc.) within timeline and budget
  • Author or Review SDTM and ADaM specifications to ensure compliant to CDISC standards
  • Review key clinical study or program documents
  • Develop SAS code, manage macro library and templates for efficiently preparing, processing, analyzing clinical data, and validating analysis results
  • Author and/or review statistical analysis related SOPs
  • Stay current with industry trends, best practices, and emerging technologies in statistical programming and data analysis
  • Additional duties and responsibilities as required

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create more effective therapies for cancer patients. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies. They collaborate with larger firms, like Gilead Sciences, to co-develop therapies, which helps them secure funding and speed up the development process. Their goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Stage

N/A

Total Funding

$341.4M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

4%

1 year growth

22%

2 year growth

90%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tango's recent $80 million private placement financing strengthens their financial position and supports ongoing R&D efforts.
  • The company's ability to secure Orphan Drug Designation and Fast Track Designation for their therapies highlights their potential to bring innovative treatments to market quickly.
  • Participation in high-profile investor conferences and scientific meetings enhances Tango's visibility and credibility in the biotech community.

What critics are saying

  • The discontinuation of the TNG348 program due to liver toxicity raises concerns about the safety and viability of their drug candidates.
  • The highly competitive oncology market requires continuous innovation and successful clinical trials to maintain a leading position.

What makes Tango Therapeutics unique

  • Tango Therapeutics leverages the principle of synthetic lethality to develop cancer treatments, a unique approach that specifically targets cancer cells while sparing healthy ones.
  • Their strategic collaborations with larger pharmaceutical companies like Gilead Sciences provide financial support and accelerate the development and commercialization of their therapies.
  • Tango's robust pipeline and focus on precision oncology, including targeting MTAP-deleted solid tumors and BRCA1/2 mutations, set them apart in the oncology market.

Help us improve and share your feedback! Did you find this helpful?